Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Neuroendocrine Cancers

  • You have access
    Comparison of 68Ga-DOTA-NOC and 18F-DOPA PET/CT in patients with neuroendocrine tumours (NETs)
    Abhishek Kumar, C. Bal, Sellam Karunanithi, Jaya Shukla, Tushar Mohapatra, Arun Malhotra and Guru Bandopadhyaya
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 407;
  • You have access
    90Y-DOTATOC therapy in patients with metastatic radioiodine negative differentiated thyroid cancer: Preliminary results
    Annibale Versari, Angelina Filice, Andrea Frasoldati, Nadia Cremonini, Mattia Asti, Federica Fioroni, Alessandro Fraternali, Massimiliano Casali and Diana Salvo
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 403;
  • You have access
    Ga68-DOTANOC uptake in the pancreas: Pathological significance?
    Yodphat Krausz, Rina Rubinstein, Eyal Mishani, Marina Orevi, Sagi Tshori, Asher Salmon, Benjamin Glaser, Roland Chisin, David Gross and Nanette Freedman
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 406;
  • You have access
    A comparison of 68Gallium-DOTA-TOC and 18F-FDG PET/CT in imaging of neuroendocrine tumors (NETs)
    Niraj Naswa, C. Bal, Snehlata Lata, Ramamohan Reddy and Arun Malhotra
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 405;
  • You have access
    99mTc-Demogastrin 2 for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
    Alida Fröberg, Berthold Nock, Thea Maina, Marion De Jong, Wouter De Herder, Casper Van Eijck, Marion Smits, Caroline Hijmans, Wouter Breeman and Eric Krenning
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 402;
  • You have access
    Superior value of [18F]6-FDOPA PET/CT in staging of neuroendocrine tumors
    Valerie Yakemchuk, Robert Reid, Pierre Major, Raman Chirakal, Karen Gulenchyn, Rebecca Olson and Pieter Jager
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 408;
  • You have access
    Somatostatin-receptor PET/CT for in-vivo quantification of receptor density - Correlation with immunohistochemistry using novel monoclonal and polyclonal antibodies
    Luisa Goetze, Vikas Prasad, Daniel Kaemmerer, Merten Hommann, Lupp Amelie, Joerg Saenger, Stefan Schulz and Richard Baum
    Journal of Nuclear Medicine May 1, 2010, 51 (supplement 2) 404;
SNMMI

© 2025 SNMMI

Powered by HighWire